Heron Therapeutics
HRTX
189 hedge funds and large institutions have $1.61B invested in Heron Therapeutics in 2021 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 65 increasing their positions, 48 reducing their positions, and 39 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
65% more call options, than puts
Call options by funds: $6.24M | Put options by funds: $3.78M
35% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 48
9% more capital invested
Capital invested by funds: $1.48B → $1.61B (+$130M)
2.29% more ownership
Funds ownership: 99.71% → 102% (+2.3%)
2% less funds holding
Funds holding: 193 → 189 (-4)
10% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$126M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$34M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$33.4M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$23.3M |
| 5 |
JP Morgan Chase
New York
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$55.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$25.9M |
| 3 |
Millennium Management
New York
|
-$11.3M |
| 4 |
Goldman Sachs
New York
|
-$8.47M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$8.45M |
HRTX Hedge Fund Activity: Q2 2021 in Review
189 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2021, worth a combined $1.61B — up 8.7% from $1.48B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of HRTX and 35 opened new positions — a net loss of 4 holders — while 48 trimmed existing stakes and 65 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $126M. The largest seller was ClearBridge Investments, exiting entirely with an estimated $55.7M sold.
- 189 institutional investors held Heron Therapeutics (HRTX) as of Q2 2021, down from 193 in Q1 2021.
- Funds reported $1.61B of Heron Therapeutics stock for Q2 2021, up 8.7% quarter-over-quarter.
- 35 funds opened new Heron Therapeutics positions in Q2 2021 and 39 closed out, a net change of -4 holders.
- The largest Heron Therapeutics buyer in Q2 2021 was Tang Capital Management, an estimated $126M added.
- The largest Heron Therapeutics seller in Q2 2021 was ClearBridge Investments, an estimated $55.7M sold.
Based on aggregated 13F filings for Q2 2021.